Publicaciones en las que colabora con Dolores Ochoa Mazarro (33)

2024

  1. Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain

    Clinical and Translational Science, Vol. 17, Núm. 1

2023

  1. Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers

    Journal of Personalized Medicine, Vol. 13, Núm. 3

2021

  1. Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin

    Frontiers in Pharmacology, Vol. 12

  2. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling

    Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270

  3. High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects

    Frontiers in Pharmacology, Vol. 12

  4. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers

    Biomedicine and Pharmacotherapy, Vol. 133

  5. Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery

    Clinical Therapeutics, Vol. 43, Núm. 5, pp. e86-e102

  6. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics

    Advances in Therapy, Vol. 38, Núm. 2, pp. 1035-1054

  7. PriME-PGX: La Princesa university hospital multidisciplinary initiative for the implementation of pharmacogenetics

    Journal of Clinical Medicine, Vol. 10, Núm. 17

  8. Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial

    Human Psychopharmacology, Vol. 36, Núm. 1, pp. 1-12

2020

  1. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran

    Advances in Therapy, Vol. 37, Núm. 8, pp. 3537-3550

  2. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

    BMC Pharmacology and Toxicology, Vol. 21, Núm. 1

  3. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates

    Biomedicines, Vol. 8, Núm. 4

  4. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 126, Núm. 3, pp. 236-246

  5. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers

    Pharmacogenomics Journal, Vol. 20, Núm. 2, pp. 235-245

  6. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics

    Pharmacogenomics, Vol. 21, Núm. 10, pp. 663-675

  7. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 10, pp. 2051-2062

  8. Urgent Hospital Admissions Caused by Adverse Drug Reactions and Medication Errors—A Population-Based Study in Spain

    Frontiers in Pharmacology, Vol. 11

2019

  1. Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally

    Advances in Therapy, Vol. 36, Núm. 10, pp. 2744-2755

  2. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention

    Clinical Therapeutics, Vol. 41, Núm. 6, pp. 1199-1212.e2